C4X Discovery, AstraZeneca enter $402m partnership focused on COPD treatments
AstraZeneca will develop and market an oral therapy for the treatment of inflammatory and respiratory diseases with focus…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
29 Nov 22
AstraZeneca will develop and market an oral therapy for the treatment of inflammatory and respiratory diseases with focus…
29 Nov 22
The clinical-stage company took an immunoproteomics approach to extract and identify naturally presented MHC Class I-restricted peptides on…
28 Nov 22
The Taiwan Food and Drug Administration has granted accelerated approval designation (AAD), and South Korea’s Ministry of Food…
28 Nov 22
The South Korean biotech firm claimed that the anticancer therapy candidate could complete chemotherapy with two doses in…
25 Nov 22
The two-dose vaccine, which leverages the same mRNA technology used in the Covid-19 vaccines developed by Pfizer and…
25 Nov 22
The MAA submission to the MHRA for NPC and ESCC indications is based on findings from the JUPITER-02…
24 Nov 22
Skyrizi is a humanised monoclonal antibody inhibitor that selectively targets interleukin-23 (IL-23), a cytokine involved in inflammatory processes,…
24 Nov 22
The XeriJect formulation technology will be used for producing an ultra-concentrated, ready-to-use, subcutaneous injection of the ophthalmic drug
23 Nov 22
Hemgenix is a gene therapy that promotes continuous production of factor IX to reduce abnormal bleeding in people…
23 Nov 22
Mary created LOLA Snacks to feed her family during a time when they were receiving food assistance